Home/Pipeline/HSK16149

HSK16149

Neuropathic Pain

Phase IIIActive

Key Facts

Indication

Neuropathic Pain

Phase

Phase III

Status

Active

Company

Haisco Pharmaceutical Group

About Haisco Pharmaceutical Group

Haisco Pharmaceutical Group's mission is to develop and deliver innovative, high-quality medicines to address unmet medical needs in China and globally. The company has achieved significant scale, becoming one of China's top pharmaceutical firms by market value, through a successful 'generic-to-innovative' transition strategy. Its core strategy is built on vertical integration, using stable cash flows from its generics and established drug portfolio to fund R&D in high-growth therapeutic areas, while expanding its commercial reach across China's vast healthcare market.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Respiratory Metabolic Central Nervous System

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
ZYNPN	Zyneyro	Pre-clinical	Active
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
ONO-2910	Ono Pharmaceutical	Phase 2	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
BDT272	KYORIN Pharmaceutical	Preclinical	Active (In-licensed)
GRC-301	Grace Therapeutics	Preclinical	Candidate optimization